Overview of Precigen's Recent Offering
Precigen, Inc. (Nasdaq: PGEN) is making headlines with its latest financial maneuver. The company has recently announced a significant private placement offering of 8.00% Series A Convertible Perpetual Preferred Stock. This effort aims to raise a total of $79 million, paving the way for continued investment in innovative gene and cell therapies.
Details of the Private Placement
The private placement is set to provide Precigen with gross proceeds of $79 million before expenses related to the offering are deducted. In conjunction with this, investors will have the opportunity to purchase warrants, allowing them to acquire up to 52,666,669 shares of common stock at an inviting exercise price of $0.75 per share.
Investor Participation and Strategy
The lead for this private placement has been assumed by affiliates of Patient Capital Management, with notable participation from recognized figures like Bill Miller and Randal J. Kirk, who serves as the executive chairman of Precigen's board of directors.
Utilization of Proceeds
The funds obtained from this offering will be directed towards working capital and other general corporate purposes. This financial injection is expected to extend Precigen's cash runway well into 2026, facilitating its upcoming commercialization efforts, particularly for the anticipated launch of PRGN-2012 in the latter half of 2025, contingent upon appropriate approvals.
Preferred Stock Features
The Preferred Stock will provide annual dividends in cash, conditional upon declaration by the board of directors. Initially, dividends will be paid in kind for the first two years, increasing the liquidation preference of the stock and accompanying it with warrants for additional shares of common stock. The Preferred Stock is redeemable at Precigen's discretion beginning from the issue date, ensuring flexibility in handling these financial tools.
Conversion and Warrant Terms
Holders of the Preferred Stock will be able to convert their shares into common stock after six months from the issuance date upon receiving the necessary shareholder approvals. The Warrants, also subject to this approval, provide a strategic option for investors to increase their stake in Precigen's future.
Importance of the Conversion Price
The conversion price is set at approximately $1.125, marking a strategic value reflective of the associated warrants' pricing. This rate is subject to adjustments, aligning with the common stock's valuation. Such flexibility allows Precigen to maintain a responsive approach to market fluctuations.
Upcoming Regulatory Filings
Precigen is aware of the regulatory landscape and plans to outline additional information about the Preferred Stock and Warrants in an upcoming Form 8-K submission to the U.S. Securities and Exchange Commission. This step demonstrates their commitment to transparency and compliance in the financial community.
General Securities Offering Information
It is important to note that the securities being offered have yet to be registered under the Securities Act of 1933, implicating significant regulatory considerations in their issuance. These securities are specifically designed for private placement, adhering to the requirements set forth to ensure appropriateness of their distribution.
About Precigen
Precigen (Nasdaq: PGEN) stands at the forefront of biopharmaceutical innovation, particularly in the realm of gene and cell therapies. The company is dedicated to developing solutions targeting urgent healthcare needs. Working in core areas such as immuno-oncology and infectious diseases, Precigen is focused on delivering affordable biotherapeutics through controlled technologies.
Frequently Asked Questions
What is the purpose of the $79 million offering?
The funds will be used for working capital and general corporate purposes to aid in the development of Precigen's therapies.
Who are the key investors in this private placement?
Affiliates of Patient Capital Management led the offering, with significant participation from Bill Miller and Randal J. Kirk.
What are the expected benefits of the Preferred Stock?
The Preferred Stock offers a way for investors to gain dividends, warrants, and a potential avenue for conversion into common stock.
Can the Preferred Stock be converted into common shares?
Yes, it can be converted into common stock after six months, pending shareholder approval.
When is Precigen expecting to launch PRGN-2012?
The anticipated launch for PRGN-2012 is in the second half of 2025, depending on approvals and market conditions.
